Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

A Phase I/II Trial of ELI-002 7P Immunotherapy as Treatment for Patients With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Solid Tumors

Summary

The purpose of this phase I/II trial is to evaluate the safety and efficacy of ELI-002 7P immunotherapy as adjuvant treatment in patients with KRAS/NRAS mutated solid tumors, including pancreatic cancer.

General Information

NCT#: NCT05726864
Study ID: ELI-002-201
Trial Phase: Phase I/II

Trial Sponsor: Elicio Therapeutics
Therapies Used in This Trial: ELI-002 7P

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search